Ocular side effects of systemic isotretinoin – a systematic review and summary of case reports

References

• Brzezinski P, Borowska K, Chiriac A, et al. Adverse effects of isotretinoin: a large, retrospective review. Dermatol Ther. 2017;30(4):1.
   Web of Science ®Google Scholar
• Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162–12.
   PubMedGoogle Scholar
• Vallerand IA, Lewinson RT, Farris MS, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018;178(1):76–85.
   PubMed Web of Science ®Google Scholar
• Ruiz-Lozano RE, Hernández-Camarena JC, Garza-Garza LA, et al. Isotretinoin and the eye: a review for the dermatologist. Dermatol Ther. 2020;33(6):e14029.
   PubMed Web of Science ®Google Scholar
• Charakida A, Mouser PE, Chu AC. Safety and side effects of the acne drug, oral isotretinoin. Expert Opin Drug Saf. 2004;3(2):119–129.
   PubMedGoogle Scholar
• Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001;132(3):299–305.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(2):d5928–d5928.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
   PubMed Web of Science ®Google Scholar
• Nyaga VN, Arbyn M, Aerts M. Metaprop: a stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72(1):1–10.
   PubMedGoogle Scholar
• Gursoy H, Cakmak I, Yildirim N, et al. Presumed isotretinoin-induced, concomitant autoimmune thyroid disease and ocular myasthenia gravis: a case report. Case Rep Dermatol. 2012;4(3):256–260.
   PubMedGoogle Scholar
• Lee AG. Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis. 1995;55(3):165–168.
   PubMed Web of Science ®Google Scholar
• Maclean H, Wright M, Choi D, et al. Abnormal night vision with isotretinoin therapy for acne [3]. Clin Exp Dermatol. 1995;20(1):86.
   PubMed Web of Science ®Google Scholar
• Nugroho J, Schweiger B. Isotretinoin as a possible environmental trigger to autoimmunity in genetically susceptible patients. Case Rep Pediatr. 2017;2017:4207656.
   PubMedGoogle Scholar
• Finsterer J. Enhanced ocular isotretinoin toxicity in mitochondrial disorder. South Med J. 2008;101(6):664–665.
   PubMed Web of Science ®Google Scholar
• Berg G, Andersson T, Sjödell L, et al. Development of severe thyroid-associated ophthalmopathy in a patient with disseminated thyroid cancer treated with recombinant human thyrotropin/radioiodine and retinoic acid. Thyroid. 2005;15(12):1389–1394.
   PubMed Web of Science ®Google Scholar
• Üstüner P. Angioedema due to systemic isotretinoin therapy. Case Rep Dermatol Med. 2014;2014:595914.
   PubMedGoogle Scholar
• Hazen P, Carney J, Langston R, et al. Corneal effect of isotretinoin: possible exacerbation of corneal neovascularization in a patient with the keratitis, ichthyosis, deafness (“KID”) syndrome. J Am Acad Dermatol. 1986;14(1):141–142.
   PubMed Web of Science ®Google Scholar
• Buyuktortop N, Onaran Z, Özkal F, et al. Central serous chorioretinopathy probably associated with isotretinoin in a keratoconus patient. Can J Ophthalmol. 2018;53(4):e162–e165.
   PubMed Web of Science ®Google Scholar
• Pérez-Pérez L, García-Gavín J, Allegue F, et al. Optic neuritis probably induced by isotretinoin. Actas Dermosifiliogr. 2012;103(9):843–844.
   PubMedGoogle Scholar
• Saray Y, Seçkin D. Angioedema and urticaria due to isotretinoin therapy [13]. J Eur Acad Dermatol Venereol. 2006;20(1):118–120.
   PubMed Web of Science ®Google Scholar
• Gurel G, Sacmaci H. Blepharospasm induced by systemic isotretinoin. Akad Acil Tip Olgu Sunumlari Derg. 2019;10(2):33–35.
   Google Scholar
• Mishra KK, Scholey JE, Daftari IK, et al. Oral isotretinoin and topical retinoid use in a series of young patients with ocular melanoma. Am J Ophthalmol Case Rep. 2020;19:100787.
   PubMedGoogle Scholar
• Feldman RJ, Maize JC. Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. Int J Dermatol. 2007;46(1):77–79.
   PubMed Web of Science ®Google Scholar
• Kiratli H, Dikmetaş O. Bilateral lacrimal gland enlargement associated with isotretinoin treatment. Ophthalmic Plast Reconstr Surg. 2013;29(6):e156–e157.
   PubMed Web of Science ®Google Scholar
• Saraswat A. Sudden irreversible worsening of myopia with isotretinoin treatment. Indian J Dermatol Venereol Leprol. 2011;77(5):611–612.
   PubMed Web of Science ®Google Scholar
• Wenham CJ, Clarke I, Shun Shin GA. Isotretinoin-related optic disc swelling. Br J Hosp Med. 2005;66(11):644–645.
   Web of Science ®Google Scholar
• Herman DC, Dyer J. Anterior subcapsular cataracts as a possible adverse ocular reaction to isotretinoin. Am J Ophthalmol. 1987;103(2):236–237.
   PubMed Web of Science ®Google Scholar
• Madke B, Prasad K, Kar S. Isotretinoin-induced night blindness. Indian J Dermatol. 2015;60(4):424.
   PubMed Web of Science ®Google Scholar
• Palestine AG. Transient acute myopia resulting from isotretinoin (accutane) therapy. Ann Ophthalmol. 1984;16(7):660–662.
   PubMedGoogle Scholar
• Alam MS, Agarwal S. Presumed isotretinoin-induced extraocular myopathy. J Pharmacol Pharmacother. 2016;7(4):187–189.
   PubMedGoogle Scholar
• Rosen E, Raz J, Segev F. Giant cobblestone-like papillae during isotretinoin therapy. Ocul Immunol Inflamm. 2009;17(5):312–313.
   PubMed Web of Science ®Google Scholar
• Halpagi P, Grigg J, Klistorner A, et al. Night blindness following low-dose isotretinoin. J Eur Acad Dermatol Venereol. 2008;22(7):893–894.
   PubMed Web of Science ®Google Scholar
• Azurdia RM, Sharpe GR. Isotretinoin treatment for acne vulgaris and its cutaneous and ocular side-effects. Br J Dermatol. 1999;141(5):947.
   PubMed Web of Science ®Google Scholar
• Citirik M, Tekin K. Excessive serous retinal detachment during the use of isotretinoin. Int Ophthalmol. 2018;38(2):763–766.
   PubMed Web of Science ®Google Scholar
• Malone C. Isotretinoin induced granulomatosis with polyangitis. J Hosp Med. 2018;13(4):Supplement 1.
   Google Scholar
• Arman A, Demirseren DD, Akoglu G. Tolerance to systemic isotretinoin therapy in two patients using highly wettable contact lenses. Case Rep Ophthalmol Med. 2014;2014:452462.
   PubMedGoogle Scholar
• Labiris G, Katsanos A, Karapetsa M, et al. Association between isotretinoin use and Central retinal vein occlusion in an adolescent with minor predisposition for thrombotic incidents: a case report. J Med Case Reports. 2009;3(1):58.
   PubMedGoogle Scholar
• Johnson M, O’Colmain U, Affleck A. Recurrent corneal erosion syndrome associated with oral isotretinoin: a cautionary tale. Clin Exp Dermatol. 2016;41(5):564.
   PubMed Web of Science ®Google Scholar
• Park YM, Lee TE. Isotretinoin-induced angle closure and myopic shift. J Glaucoma. 2017;26(11):e252–e254.
   PubMed Web of Science ®Google Scholar
• Barbosa AP, Oliveira FR, da Rocha FJ, et al. Lacrimal gland atrophy and dry eye related to isotretinoin, androgen, and prolactin: differential diagnosis for Sjögren’s syndrome. Arq Bras Oftalmol. 2021;84(1):78–82.
   PubMed Web of Science ®Google Scholar
• Roytman M, Frumkin A, Bohn TG. Pseudotumor cerebri caused by isotretinoin. Cutis. 1988;42(5):399–400.
   PubMedGoogle Scholar
• Martínez-González MC, García-Silva J, Sánchez MA, et al. Acute myopia while on oral isotretinoin treatment. J Eur Acad Dermatol Venereol. 2007;21(7):977–978.
   PubMed Web of Science ®Google Scholar
• Elpern DJ. Isotretinoin and one patient’s teary eyes: “please listen or I’ll cry. Int J Dermatol. 2013;52(6):757–758.
   PubMed Web of Science ®Google Scholar
• Chua WC, Martin PA, Kourt G. Watery eye: a new side-effect of isotretinoin therapy. Eye . 2001;15(Pt 1):115–116.
   PubMedGoogle Scholar
• Welsh BM, Smith AL, Elder JE, et al. Night blindness precipitated by isotretinoin in the setting of hypovitaminosis A. Australas J Dermatol. 1999;40(4):208–210.
   PubMedGoogle Scholar
• Özcan AA, Soylu M. Transient corneal opacity after use of oral isotretinoin. Ann Med Sci. 2002;11(2–4):71–72.
   Google Scholar
• Ellies P, Dighiero P, Legeais JM, et al. Persistent corneal opacity after oral isotretinoin therapy for acne. Cornea. 2000;19(2):238–239.
   PubMed Web of Science ®Google Scholar
• Watson NJ, Hutchinson CH. Rod and cone malfunction as a manifestation of isotretinoin therapy. J Dermatolog Treat. 1992;3(4):205–207.
   Google Scholar
• Onder HI, Turan H, Kilic AC, et al. Premacular hemorrhage due to isotretinoin use. Cutan Ocul Toxicol. 2013;32(2):170–172.
   PubMed Web of Science ®Google Scholar
• Bigby M, Stern RS. Adverse reactions to isotretinoin. A report from the adverse drug reaction reporting system. J Am Acad Dermatol. 1988;18(3):543–552.
   PubMed Web of Science ®Google Scholar
• Ersoz MG, Gunes IB, Hazar L, et al. Ocular surface epithelial thickness changes with SD-OCT in patients treated with oral isotretinoin. Int Eye Sci. 2018;18(1):7–11.
   Google Scholar
• Yılmaz U, Küçük E, Koç Ç, et al. Investigation of the effects of systemic isotretinoin treatment on retinal nerve fiber layer and macula. J Dermatolog Treat. 2017;28(4):314–317.
   PubMed Web of Science ®Google Scholar
• Yavuz C, Ozcimen M. An evaluation of peripapillar choroidal thickness in patients receiving systemic isotretinoin treatment. Cutan Ocul Toxicol. 2019;38(1):25–28.
   PubMed Web of Science ®Google Scholar
• Yuksel N, Ozer MD, Akcay E, et al. Reduced Central corneal thickness in patients with isotretinoin treatment. Cutan Ocul Toxicol. 2015;34(4):318–321.
   PubMed Web of Science ®Google Scholar
• Karadag O, Kocamaz M, Dastan M, et al. Assessment of macular choroidal thickness, Central macular thickness and retinal nerve fiber layer in patients receiving oral isotretinoin treatment. Cutan Ocul Toxicol. 2020;39(3):233–236.
   PubMed Web of Science ®Google Scholar
• Ucak H, Aykut V, Ozturk S, et al. Effect of oral isotretinoin treatment on retinal nerve fiber layer thickness. J Cutan Med Surg. 2014;18(4):236–242.
   PubMed Web of Science ®Google Scholar
• Ozyol P, Ozyol E, Yildirim FE. Remodeling of cornea with isotretinoin treatment. Eye Contact Lens. 2020;47(6):366–371.
   Web of Science ®Google Scholar
• Hodgkiss-Harlow CJ, Eichenfield LF, Dohil MA. Effective monitoring of isotretinoin safety in a pediatric dermatology population: a novel “patient symptom survey” approach. J Am Acad Dermatol. 2011;65(3):517–524.
   PubMed Web of Science ®Google Scholar
• Brown RD, Grattan CE. Visual toxicity of synthetic retinoids. Br J Ophthalmol. 1989;73(4):286–288.
   PubMed Web of Science ®Google Scholar
• de Queiroga IBW, Vieira LA, de Nadai Barros J, et al. Conjunctival impression cytology changes induced by oral isotretinoin. Cornea. 2009;28(9 PG-1009-13):1009–1013.
   PubMed Web of Science ®Google Scholar
• Yeh TN, Lin MC. Isotretinoin study: ocular surface comparison between exposed and unexposed groups. Investig Ophthalmol Vis Sci. 2016;57(12):2856.
   Web of Science ®Google Scholar
• Fouladgar N, Khabazkhoob M, Hanifnia AR, et al. Evaluation of the effects of isotretinoin for treatment of acne on corneal sensitivity. J Curr Ophthalmol. 2018;30(4):326–329.
   PubMed Web of Science ®Google Scholar
• Wn M. How safe is oral isotretinoin? Dermatology. 1997;195:22–28.
   PubMed Web of Science ®Google Scholar
• Strauss JS, Gottlieb AB, Jones T, et al. Concomitant administration of vitamin E does not change the side effects of isotretinoin as used in acne vulgaris: a randomized trial. J Am Acad Dermatol. 2000;43(5 Pt 1):777–784.
   PubMed Web of Science ®Google Scholar
• McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol. 2001;45(5):S188–S194.
   PubMed Web of Science ®Google Scholar
• Layton AM, Cunliffe WJ. Ocular problems in contact lens wearers and non-contact lens wearers on isotretinoin – practical guidelines. J Dermatolog Treat. 1990;1(5):247–249.
   Google Scholar
• Aydogan K, Turan OF, Onart S, et al. Neurological and neurophysiological effects of oral isotretinoin: a prospective investigation using auditory and visual evoked potentials. Eur J Dermatol. 2008;18(6):642–646.
   PubMed Web of Science ®Google Scholar
• Neudorfer M, Goldshtein I, Shamai-Lubovitz O, et al. Ocular adverse effects of systemic treatment with isotretinoin. Arch Dermatol. 2012;148(7):803–808.
   PubMedGoogle Scholar
• Demirseren DD, Kilinc F, Emre S, et al. The weeks and the cumulative doses of the first adverse events related to oral isotretinoin in acne patients: analysis of 300 patients. J Dermatolog Treat. 2017;28(4):309–313.
   PubMed Web of Science ®Google Scholar
• Mirnezami M, Rahimi H. Is oral omega-3 effective in reducing mucocutaneous side effects of isotretinoin in patients with acne vulgaris? Dermatol Res Pract. 2018;2018:1–4.
   Web of Science ®Google Scholar
• Düzgün E, Özkur E. The effect of oral isotretinoin therapy on meibomian gland morphology and dry eye tests. J Dermatolog Treat. 2022;33(2):762–768.
   PubMed Web of Science ®Google Scholar
• Hafeez L, Khan AN, Aslam A, et al. Comparison of safety and efficacy of low dose isotretinoin versus the conventional dosing regime in the treatment of acne vulgaris. J Pakistan Assoc Dermatologists. 2020;30(3):423–427.
   Google Scholar
• Blackman HJ, Peck GL, Olsen TG, et al. Blepharoconjunctivitis: a side effect of 13-cis-retinoic acid therapy for dermatologic diseases. Ophthalmology. 1979;86(5):753–759.
   PubMed Web of Science ®Google Scholar
• Milson J, Jones DH, King K, et al. Ophthalmological effects of 13-cis-retinoic acid therapy for acne vulgaris. Br J Dermatol. 1982;107(4):491.
   PubMed Web of Science ®Google Scholar
• Clamon G, Chabot GG, Valeriote F, et al. Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acid. Cancer Res. 1985;45(4):1874–1878.
   PubMed Web of Science ®Google Scholar
• Egger SF, Huber-Spitzy V, Böhler K, et al. Ocular side effects associated with 13-cis-retinoic acid therapy for acne vulgaris: clinical features, alterations of tearfilm and conjunctival flora. Acta Ophthalmol Scand. 1995;73(4):355–357.
   PubMedGoogle Scholar
• Hull PR, Demkiw-Bartel C. Isotretinoin use in acne: prospective evaluation of adverse events. J Cutan Med Surg. 2000;4(2):66–70.
   PubMedGoogle Scholar
• Strauss JS, Leyden JJ, Lucky AW. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol. 2001;45(2):196–207.
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Irkeç MT, Atakan N, et al. Lacrimal function and ocular complications in patients treated with systemic isotretinoin. Eur J Ophthalmol. 2002;12(3):173–176.
   PubMed Web of Science ®Google Scholar
• Oner A, Ferahbas A, Karakucuk S, et al. Ocular side effects associated with systemic isotretinoin. J Toxicol – Cutan Ocul Toxicol. 2005;23(3):189–195.
   Web of Science ®Google Scholar
• Mathers WD, Shields WJ, Sachdev MS, et al. Meibomian gland morphology and tear osmolarity: changes with accutane therapy. Cornea. 1991;10(4):286–290.
   PubMed Web of Science ®Google Scholar
• Aragona P, Cannavò SP, Borgia F, et al. Utility of studying the ocular surface in patients with acne vulgaris treated with oral isotretinoin: a randomized controlled trial. Br J Dermatol. 2005;152(3):576–578.
   PubMed Web of Science ®Google Scholar
• Karalezli A, Borazan M, Altinors DD, et al. Conjunctival impression cytology, ocular surface, and tear-film changes in patients treated with systemic isotretinoin. Cornea. 2009;28(1):46–50.
   PubMed Web of Science ®Google Scholar
• Yildirim Y, Olcucu O, Agca A, et al. Evaluation of corneal topography and biomechanical parameters after use of systemic isotretinoin in acne vulgaris. J Ophthalmol. 2014;2014:701361.
   PubMed Web of Science ®Google Scholar
• Caglar C, Senel E, Sabancilar E, et al. Reduced ocular surface disease index (OSDI) scores in patients with isotretinoin treatment. Int Ophthalmol. 2017;37(1):197–202.
   PubMed Web of Science ®Google Scholar
• Polat M, Kükner Ş. The effect of oral isotretinoin on visual contrast sensitivity and amount of lacrimation in patients with acne vulgaris. Cutan Ocul Toxicol. 2017;36(1):35–38.
   PubMed Web of Science ®Google Scholar
• Elhamaky TR. Efficacy of omega-3 fatty acids and punctal plugs in the prevention of isotretinoin-associated ocular surface disease. Eur J Ophthalmol. 2020;31(5):2339–2345.
   PubMed Web of Science ®Google Scholar
• Cumurcu T, Sezer E, Kilic R, et al. Comparison of dose-related ocular side effects during systemic isotretinoin administration. Eur J Ophthalmol. 2009;19(2):196–200.
   PubMed Web of Science ®Google Scholar
• Lester RS, Schachter GD, Light MJ. Isotretinoin and tetracycline in the management of severe nodulocystic acne. Int J Dermatol. 1985;24(4):252–257.
   PubMed Web of Science ®Google Scholar
• Goulden V, Layton AM, Cunliffe WJ. Long-term safety of isotretinoin as a treatment for acne vulgaris. Br J Dermatol. 1994;131(3):360–363.
   PubMed Web of Science ®Google Scholar
• Ahmed I, Wahid Z, Nasreen S. Adverse effects of systemic isotretinoin therapy: a study of 78 patients. J Pak Assoc Dermatolog. 2005;15(3):242–246.
   Google Scholar
• Kaymak Y, Ilter N. The results and side effects of systemic isotretinoin treatment in 100 patients with acne vulgaris. Dermatol Nurs. 2006;18(6):576–580.
   PubMedGoogle Scholar
• Demirok G, Topalak Y, Gündüz Ö, et al. The long-term effect of oral isotretinoin therapy on macula ganglion cell complex thickness. Cutan Ocul Toxicol. 2017;36(3):259–262.
   PubMed Web of Science ®Google Scholar
• Denman S, Weleber R, Hanifin JM, et al. Abnormal night vision and altered dark adaptometry in patients treated with isotretinoin for acne. J Am Acad Dermatol. 1986;14(4):692–693.
   PubMed Web of Science ®Google Scholar
• Mollan SP, Woodcock M, Siddiqi R, et al. Does use of isotretinoin rule out a career in flying? Br J Ophthalmol. 2006;90(8):957–959.
   PubMed Web of Science ®Google Scholar
• Sekeryapan B, Dılek N, Oner V, et al. Retinal nerve fiber layer and ganglion cell layer thickness in patients receiving systemic isotretinoin therapy. Int Ophthalmol. 2013;33(5):481–484.
   PubMed Web of Science ®Google Scholar
• Satapathy J, Panigrahi PK, Kar BR. Effect of oral isotretinoin on retinal nerve fibre layer and ganglion cell layer thickness. Int J Pharm Res. 2021;13(1):3427–3432.
   Google Scholar
• Cumurcu T, Sener S, Ozsoy E, et al. Changes in anterior chamber parameters with the pentacam rotating scheimpflug and axial length measurements by ultrasound in patients who use isotretinoin. Curr Eye Res. 2012;37(5):395–398.
   PubMed Web of Science ®Google Scholar
• Yasar E, Gurlevik U, Kemeriz F, et al. Effect of isotretinoin on myopia and axial length: a pilot study. Cutan Ocul Toxicol. 2020;39(4):385–388.
   PubMed Web of Science ®Google Scholar
• Kaptı BH, Aslan G, Yavruoğlu MA. Evaluation of retinal nerve fiber layer changes with oral isotretinoin treatment. Ophthalmol Ther. 2013;2(1):19–23.
   PubMedGoogle Scholar
• Bakbak B, Gedik S, Koktekir BE, et al. Structural and functional assessment in patients treated with systemic isotretinoin using optical coherence tomography and frequency-doubling technology perimetry. Neuroophthalmology. 2013;37(3):1100–103.
   PubMed Web of Science ®Google Scholar
• Moy A, McNamara NA, Lin MC. Effects of isotretinoin on meibomian glands. Optom Vis Sci. 2015;92(9):925–930.
   PubMed Web of Science ®Google Scholar
• Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71–81.
   PubMed Web of Science ®Google Scholar